Neurogene Q2 net loss $34.5M; NGN-401 100% milestone gains; cash to 1Q29

Neurogene Inc.

Q2 2026 net loss $34.5M vs $22.0M YoY; R&D $25.5M, G&A $11.2M.
Cash $225.4M at June 30; pro forma $360.2M after $134.8M net from July offering; runway into 1Q29.
NGN-401 Phase 1/2: 100% (N=10) improved CGI-I and gained ≥1 milestone; avg 4.7 milestones, no plateau through 30 months.
Embolden topline data expected 2H 2027; PPQ runs for BLA complete by end-2026; NGN-401 well-tolerated (N=35).
Oversubscribed public offering raised ~$144M gross proceeds, including full underwriter option exercise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.